Tag Archives: technology

Discover Early-Stage Life Science Opportunities at London Bio-Innovation Week

18 Nov

By Greg Mannix, VP, EMEA Business Development, LSN

Educational sessions, networking, and investor partnering, December 2–5, 2025 

London Bio-Innovation Week brings together the global life science community for a series of premier events focused on early-stage innovation, taking place December 2–5, 2025. The week offers a unique combination of educational programming, networking opportunities, and investor partnering across multiple sectors of the life sciences. 

Participating events include RESI London by Life Science Nation, Genesis Conference by One Nucleus, the SLAS–ELRIG Meet-up, Advanced Therapies Integrates by LSI, and several free educational programs. Together, these events create an ecosystem where scientists, entrepreneurs, investors, and industry dealmakers can connect and collaborate. 

Opportunities at London Bio-Innovation Week include: 

  • Scientists engage with those commercializing innovations. 
  • Investors and industry dealmakers are discovering the next breakthroughs. 
  • Early-stage investors meet entrepreneurs seeking capital. 
  • Life science dealmakers are gaining early access to cutting-edge technologies. 
  • Building meaningful connections across the life science ecosystem. 

Join us for our upcoming webinar, that will provide an overview of London Bio-Innovation Week, highlighting how the events can help advance your company, discover investment opportunities, and connect with key partners. 

Webinar Speakers: 

  • Sougato Das, President & COO, Life Science Nation 
  • Tony Jones, Chief Executive Officer, One Nucleus 
  • Vicki Loise, Chief Executive Officer, SLAS (Society for Laboratory Automation and Screening) 
  • Sanj Kumar, Chief Executive Officer, ELRIG 

Webinar Details: 

  • Date & Time: November 20, 2025, 9:00 AM Eastern Time (US & Canada) 

Register RESI London now to explore all the ways London Bio-Innovation Week can support your early-stage life science goals and connect you with the right partners. 

Register for RESI London

Navigating JPM Week: A Guide to RESI’s 2026 Event Lineup 

18 Nov

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

As the life science world converges on San Francisco for J.P. Morgan Healthcare Week in January 2026, the RESI Conference plays a central role, and its website’s dedicated “JPM Week Events” page is an essential resource for attendees and stakeholders alike. Here’s a breakdown of what the site offers and why it’s such a valuable hub. 

What Is the JPM Week Events Page? 

The RESI “JPM Week Events” page is essentially a curated calendar and guide, maintained by Life Science Nation. It compiles an exhaustive list of life science–oriented events happening in parallel with JPM Healthcare Week, from early morning breakfasts to high-level receptions and symposiums.  

It’s not just a list; it’s a strategic tool for entrepreneurs, investors, and corporates to plan how to maximize their time during one of the most frenetic weeks in biotech and healthcare investments. 

What’s on the Agenda: Highlights from the 2026 Schedule 

Here is some standout events listed for January 2026 on RESI’s page: 

January 10–11: 

  • San Francisco CEO | Longwood Healthcare Leaders Forum — A full-day leadership forum at the Four Seasons.  
  • 9th Annual Neuroscience Innovation Forum — Focused on business development, licensing, and investment, held at the Marines’ Memorial Club.  
  • PwC Executive Women’s Event — A networking event aimed at women leaders in healthcare.  
  • Yafo Capital ACCESS ASIA BD Forum — A cross-border business development forum in San Francisco.  

January 12: 

  • RESI JPM 2026 Conference at the San Francisco Marriott Marquis.  
  • AcuityMD Sunrise Partnering Breakfast — An early morning session for high-value partnering.  
  • AdvaMed Member Meeting Space & Receptions — Dedicated space for AdvaMed members.  
  • Incubate & DLA Piper: Innovation at a Crossroads — A policy-focused discussion on biopharma strategy in a changing global landscape.  
  • Lifeblood & Goodwin MedTech CEO-only Forum — A specialized gathering for medtech CEOs.  
  • MassBio Meeting Space & Receptions — Hosted by MassBio at the Parc 55 Hotel.  
  • QNova LifeSciences 12th Annual Partnering Forum — A major partnering event in the Hilton Union Square.  
  • PMI Biotech Reception — A dinner reception at InterContinental Mark Hopkins.  
  • Aquillius Pitch Showcase — A pitching event for life sciences companies. 
  • Biovia Event: Clusters of Excellence — A forum on European life science clusters and global success.  
  • T2Bmeet @ JPM — A streamlined meeting event to facilitate business development and partnering.  
  • Scale Biosciences JPM Happy Hour — Evening social for dealmakers.  
  • STAT @ JPM26 Live — A live event by STAT News.  
  • Reed Smith Reception — At the Museum of the African Diaspora. 
  • Deloitte Reception — A networking evening hosted by Deloitte.  

January 13: 

  • Continuation of RESI JPM 2026 
  • Fierce JPM Week — A track that runs throughout JPM Week, focused on dealmaking and thought leadership. 
  • Biocom California Events — Receptions, meeting space, and more at Omni San Francisco. 
  • KoreaBIO / BioCentury / Sidley Austin IR Forum — Global investor relations forum.  
  • LaunchBio & Inspira Innovators Social Hour — A more informal social event for early-stage founders.  
  • Katten’s Diptyque Client Reception — A luxury experience for select invitees. 
  • Dartmouth Offsite — Hosted at the Beacon Grand Hotel.  
  • Bits in Bio Reception — For emerging biotech companies and leaders.  

January 14–15: 

  • Multiple networking breakfasts, partnering forums, and receptions.  
  • HCPEA Women’s Mentor/Mentee Networking Breakfast on January 14. 
  • 2026 Stanford Alumni in Healthcare Networking Mixer — A Stanford alumni focused event. 
  • CTIP Innovator Showcase (Jan 15) — For pediatric technology innovators. 
  • MBC BioLabs: Meet the Founders — Founders’ networking at a biotech incubator.  
  • Toplink Conference @ JPM — A full-day conference on tech + life science.  
  • Swissnex Networking Event — International networking through the Swissnex channel.  
  • And more receptions, including PCI Pharma Services, California Israel Chamber of Commerce Israel Lounge, and Destination Medical Center Discovery Exchange.  

Why This Page Matters 

  1. Comprehensive Planning Tool: For anyone attending JPM Week — whether founders, investors, BD execs, or scientists — having a central, curated list of relevant life science events is invaluable. Rather than navigating a sea of scattered invitations, the RESI page brings together a clean, structured schedule. 
  1. Partnership Optimization: Many of the events listed are tailored for dealmaking — breakfasts, partnering forums, and pitch showcases. This makes it easier for startups to schedule and maximize high-impact interactions. 
  1. Community Spotlight: The page isn’t only about formal conferences; it also highlights social events, networking mixers, and sector-specific receptions (e.g., women in healthcare, neuroscience, medtech). This helps attendees connect on both professional and personal levels. 

The RESI “JPM Week Events” page is more than just a listing: it’s a strategic roadmap for navigating one of the busiest and most important weeks in healthcare investing. By consolidating diverse events, boardroom policy talks to rooftop cocktail receptions; it empowers life science professionals to plan smarter, connect deeper, and maximize their time. 

For anyone participating in RESI JPM 2026, bookmarking this page is one of the first steps to making the most of the week. 

Register for RESI JPM >>

Early-Stage Partnerships with Mosaic Biosciences at RESI London 

18 Nov

By Matt Stanton, VP Sales US West, Central and South America, LSN

Mara Sprouce, Director of Commercial Operations at Mosaic Biosciences, shares how their team of drug hunters and problem solvers support early-stage biotech partners from concept to candidate. In this interview, Mara discusses Mosaic’s collaborative approach to innovation, how their platform adapts to diverse modalities and target classes, and what sets them apart from a traditional CRO. She also highlights the types of partners they’re eager to meet at RESI London and what attendees can look forward to when connecting with the Mosaic team on-site.

Register for RESI London

Hot Investor Mandate: Family Office Backed Venture Fund Invests in Pre-Clinical Therapeutic Platforms Across the Globe

18 Nov

This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities. 

The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage. 

The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: VC Firm Invests in Drug Discovery Enabling Tools, Techbio, AI-Driven Applications Globally With a Focus on USA-Based Companies  

18 Nov

A pharma-tech focused venture capital firm, founded in 2022 and headquartered in the US, invests in early-stage companies and also has the capability to incubate new ventures. The firm is driven by the belief that the pharmaceutical industry represents a strong and scalable customer base, and seeks technologies that align with or enhance the pharma value chain. While open to global opportunities, the firm shows a preference for companies based in the United States. Typical investment sizes range from $2 million to $5 million, and the firm is flexible in its role, able to lead or follow in financing rounds. 

The firm invests across a broad spectrum of pharma-tech, including technologies targeting patients or providers, tech-bio platforms, drug discovery tools, AI-driven applications, supply chain innovations, and data-centric platforms. In essence, it is interested in any innovation that contributes to the pharmaceutical and life sciences value chain. The firm is disease-agnostic in its approach. 

An active investor, the firm typically takes a board seat or observer role and prefers companies that have pharmaceutical companies as at least one major customer or are built with pharma as the primary target market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: USA-Based VC Firm Seeks Longevity-Focused Investments, Engaging in Seed to Series A Rounds

18 Nov

A venture capital firm based in the US is focused on incubating and investing in longevity-focused companies that aim to improve quality of life for older adults. The firm primarily invests at the Seed and Series A stages, with typical initial check sizes ranging from $100,000 to $500,000. The investment focus is on opportunities based in the United States. 

The firm invests broadly across the life sciences and healthcare sectors, provided there is a clear connection to aging and longevity. Areas of interest include healthcare quality and cost, care capacity, healthcare benefits activation, aging in place, and financial longevity. The firm has made investments in medical devices, diagnostics, and digital health companies, and currently maintains an active portfolio of more than 15 companies. It generally does not invest in biotech. The firm is open to backing companies at the earliest stages of development. 

There are no specific requirements regarding company structure or founding team experience. The firm is flexible in its role and may choose to lead or co-invest depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Late-Stage Venture & Growth Equity Investor Backing De-Risked Therapeutics and Medical Device Opportunities

18 Nov

A venture capital and private equity firm focuses on investments in the life sciences sector, with a primary emphasis on pharmaceuticals and therapeutics, and a secondary interest in medical devices. The firm invests from Series A through growth-stage transactions and is currently deploying capital from its third fund. Typical investment sizes range from $10 million to $40 million. 

The firm prioritizes opportunities with a de-risked clinical development pathway, such as those involving repurposed or reformulated drugs, established mechanisms of action, 505(b)(2) regulatory strategies, or programs with proof-of-concept clinical data. For therapeutic assets, the firm primarily targets clinical-stage companies, ideally with completed Phase I trials. For medical devices, the firm considers clinical-stage opportunities with a clear regulatory and commercialization path. The firm is indication-agnostic but maintains a strong interest in 505(b)(2) products.  
 
The firm seeks companies with a clearly defined path to regulatory approval, supported by robust intellectual property and market exclusivity. It plays an active role in its portfolio companies and takes a board seat in every investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com